GSK (LON:GSK) Price Target Raised to GBX 2,200

GSK (LON:GSK) had its price target upped by Berenberg Bank from GBX 2,000 to GBX 2,200 in a research report issued to clients and investors on Tuesday, Digital Look reports. The firm currently has a “hold” rating on the stock. Berenberg Bank’s target price points to a potential upside of 18.38% from the stock’s current price.

GSK has been the topic of a number of other research reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,975 price objective on shares of GSK in a research report on Tuesday, September 8th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research report on Wednesday, September 2nd. Two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, GSK currently has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Price Performance

Shares of GSK opened at GBX 1,858.50 on Tuesday. The company has a market capitalization of £74.47 billion, a P/E ratio of 15.78, a P/E/G ratio of 1.24 and a beta of 0.29. GSK has a fifty-two week low of GBX 1,455 and a fifty-two week high of GBX 2,282. The business’s 50-day moving average is GBX 1,899.20 and its two-hundred day moving average is GBX 1,964.02. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last released its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Research analysts predict that GSK will post 175.980975 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Jonathan Symonds purchased 1,550 shares of the stock in a transaction that occurred on Friday, June 19th. The shares were acquired at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Also, insider Jeannie Lee acquired 802 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average cost of GBX 5,069 per share, for a total transaction of £40,653.38. Insiders purchased a total of 3,625 shares of company stock valued at $13,494,563 over the last three months. 0.20% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.